Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis? PDF Print E-mail
Thursday, 22 December 2011 20:15
Eric Hachulla, MD, PhD; David Launay, MD, PhD; Luc Mouthon, MD, PhD; Olivier Sitbon, MD, PhD; Alice Berezne, MD; Loïc Guillevin, MD; Pierre-Yves Hatron, MD; Ge´rald Simonneau, MD; Pierre Clerson, MD; and Marc Humbert, MD, PhD;

Pulmonary arterial hypertension (PAH) is a frequent complication in patients with systemic sclerosis (SSc) that has a prevalence of 8 to 12%. Within the last 2 decades, pulmonary fibrosis and PAH have become the leading causes of death in SSc patients. The estimated 3-year survival rate among patients with PAH associated with SSc is approximately 50%. The development of PAH in patients with SSc must be differentiated from that of pulmonary hypertension (PH) associated with severe pulmonary fibrosis. The latter may manifest as a significant reduction of lung volume (FVC 60% predicted and/or total lung capacity [TLC] 60%) and a modest elevation in mean pulmonary artery pressure (mPAP) of 35 mm Hg at rest.

Unlike pulmonary fibrosis, PAH is understood to occur late in the natural course of SSc and more frequently in patients with limited cutaneous SSc (lcSSc). This assertion, however, may benefit from reappraisal. Studies have shown that PAH may be similarly prevalent among patients with diffuse cutaneous SSc (dcSSc) as it is among patients with lcSSc. Robust data estimating the typical duration between the diagnosis of SSc and the diagnosis of PAH are lacking. The aim of this study was to analyze this duration and evaluate the potential relevance of “time of occurrence of PAH” in the course of SSc as a prognostic factor.

Download the full research paper from the link provided below.

 
More articles :

» Scleroderma Patients At Greater Risk Of Myocardial Infarction Within First Year

According to the first large population-based cohort study of its kind, patients with Systemic Sclerosis or were found to be at a greater than eightfold increased risk of having an acute (MI) during their first year after diagnosis. After that...

» Research Vital Statistics and Information On Virtually Any Medicine

is a useful database of information about the prescription and over-the-counter medication, allowing you to look up the possible side effects of specific drugs and see statistics about their reported problems.If you were to look up the allergy...

» What Is Autoimmune Hepatitis?

Autoimmune hepatitis is an of the caused by an autoimmune disorder. An autoimmune disorder is one in which a person's immune system attacks his or her own body for unknown reasons. The degree of liver inflammation can range from mild to deadly.The...

» Survival in Pulmonary Hypertension Associated With the Scleroderma Spectrum of Diseases

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisObjective. Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be...

» UTHealth, Fudan University Launch Scleroderma Network

Scleroderma clinicians and researchers in the United States and China have launched an international network to fight this debilitating disease that affects more than one million people worldwide.The network was established by faculty at The...

» Scleroderma Renal Crisis: A Pathology Perspective

Ibrahim Batal, Robyn T. Domsic, Thomas A.Medsger Jr., and Sheldon BastackyInternational Journal of RheumatologyVolume 2010, Article ID 543704Scleroderma renal crisis (SRC) is an infrequent but serious complication of systemic sclerosis (SSc). It is...